Splash Beverage Group Inc

Splash Beverage Group will officially change its corporate name to Endovia Health Sciences on August 2 and begin trading under the new ticker symbol EDVA. The company said the name change reflects its strategic transformation from a legacy beverage business into a diversified cannabinoid health sciences platform focused on commercializing pharmaceutical assets, advancing FDA-regulated human and veterinary therapeutics, and developing innovative cannabinoid wellness and beverage products. CEO Brady Cobb called the move the culmination of a deliberate strategic transformation. Endovia Health Sciences is being built around three complementary growth engines: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and consumer wellness and beverages.

Splash Beverage Group has expanded its exclusive global license for CannEpil to include veterinary therapeutic applications, creating a second FDA-regulated pharmaceutical development program alongside its existing human pharmaceutical program. The expanded field of use grants Splash exclusive worldwide rights to develop, manufacture, commercialize, market and distribute CannEpil for veterinary diseases and conditions. CannEpil is a proprietary pharmaceutical-grade cannabinoid formulation consisting of CBD and THC isolates manufactured under EU-GMP standards, originally developed for drug-resistant epilepsy and assigned an IND application number by the FDA for its human program. Splash intends to initially evaluate CannEpil for companion-animal oncology and chronic pain management, with canine indications as the initial focus, and will pursue U.S. regulatory approval through the FDA Center for Veterinary Medicine's INAD and Conditional Approval pathways. The global veterinary pain management market was valued at approximately $2.6 billion in 2024 and is projected to reach approximately $3.8 billion by 2030, while the veterinary oncology market is estimated between approximately $900 million and $1.7 billion. Under the license amendment, Splash will pay Argent BioPharma Limited a 10% royalty on net revenues from veterinary applications, and the company is finalizing a strategic joint venture with an established cannabinoid pharmaceutical company to lead the veterinary development program.

Splash Beverage Group has acquired exclusive global rights to CannEpil, a cannabinoid-based investigational therapy for drug-resistant epilepsy, from Argent BioPharma Limited. CannEpil is already available in multiple international markets including Ireland, the United Kingdom, Germany and Australia, and is manufactured under EU-GMP standards. The therapy has been prescribed through regulated patient-access programs, has reimbursement-supported access in Europe, and has engaged with the U.S. FDA through the pre-IND process, receiving an IND number. As part of the transaction, Splash secured a $1 million strategic investment from C/M Capital Partners to support U.S. regulatory advancement and commercialization. Under the agreement, Splash gains worldwide rights for an initial twenty-year term, with Argent BioPharma receiving a 15% royalty on net revenue, while Mercer Street Global Opportunity Fund forgave approximately $5 million of Argent BioPharma debt and Splash issued $5.5 million in preferred equity as consideration.